Premature aging

Premature aging (also known as progeroid syndromes) refers to a heterogeneous group of rare genetic disorders characterized by clinical features that resemble accelerated physiological aging. These conditions affect multiple body systems and can manifest with signs such as growth retardation, lipodystrophy (loss of subcutaneous fat), skin atrophy, alopecia (hair loss), skeletal abnormalities, joint contractures, and cardiovascular disease. Depending on the specific subtype, patients may also develop cataracts, osteoporosis, atherosclerosis, diabetes mellitus, and neurodegeneration. The most well-known conditions within this group include Hutchinson-Gilford progeria syndrome, Werner syndrome, Cockayne syndrome, and others, each caused by distinct genetic defects often involving DNA repair mechanisms, nuclear envelope proteins, or telomere maintenance pathways. The age of onset and severity vary considerably depending on the specific progeroid syndrome. Some forms present in infancy or early childhood with dramatic growth failure and aged appearance, while others may not become apparent until adolescence or adulthood. Cardiovascular complications, including premature atherosclerosis and cardiac disease, are a leading cause of morbidity and mortality in many of these conditions. Currently, there is no cure for most premature aging syndromes. Treatment is largely supportive and symptomatic, focusing on managing cardiovascular risk, orthopedic complications, and other organ-specific manifestations. For Hutchinson-Gilford progeria specifically, lonafarnib (a farnesyltransferase inhibitor) has been approved as a targeted therapy. Ongoing research into the molecular mechanisms of aging continues to inform potential therapeutic strategies for this group of disorders.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Premature aging